Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study (Q39484584)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

central nervous system lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Martin J van den Bent

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Bronno van der Holt

3

object named as

Bronno van der Holt

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

4

object named as

Harry C Schouten

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Pieternella J Lugtenburg

9

object named as

Pieternella J Lugtenburg

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Jeanette K Doorduijn

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Gustaaf W van Imhoff

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Martijn R Schaafsma

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Marius A MacKenzie

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Joke W Baars

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Marie José Kersten

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Roelien H Enting

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Fokje M Spoelstra

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Philip Poortmans

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jacoline E C Bromberg

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

17 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Hematological Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

35

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

497-503

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27530779%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Aspects concerning busulfan pharmacokinetics and bioavailability

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Acute painful lumbosacral paresthesia after intrathecal rituximab

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

21 January 2018

Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

7 January 2021

based on heuristic

inferred from DOI database lookup

Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

https://api.crossref.org/works/10.1002%2FHON.2342

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39484584&oldid=2268390001"